Sinae Gemcitabine HCl fabrica, supplementum, Factory

Jiangsu Run'an Pharmaceutical Co, Ltd., subsidiaria omnino possessa de Jiangsu Chiatai Qingjiang Pharmaceutical Co, Ltd., modernus summus tech pharmaceuticus societas specialis in R&D, productionis et venditio fertilitatis ordinandae medicinae et varietatis APIs. Project constructionem mense Novembri 2018 incepit, LIX mu aream obtegens, cum tota obsidione 160 decies Yuan et tota area aedificium 25000 quadratum metrorum.

Praecipuum activum medicamentum pharmaceuticum (API) producta: Gemcitabinum HCl, Celecoxib, bromhexinum hydrochloridum, Iguratimod, Apremilast, Citrate Tofactinib, Crisaborole, Urapidil Hydrochloride, Sugammadex Natri, Garlicin, Dexmedetomidine Hydrochloridi, Rocuronium Bromidum, Finerenone, etc. elit mundi genus facti et productorum gignentium opificem per constantem emendationem et innovationem in technologiarum, et occasiones praeclarum negotium praebent sodalibus nostris per orbem terrarum. Munus nostrum ad praestantes operas emptores nobis permisit solidas relationes cum sociis nostris toto orbe includere.

View as  
 
Anti-tumor Gemcitabine

Anti-tumor Gemcitabine

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Anti-tumor Gemcitabine
CAS#122111-03-9

Lege plusMitte Inquisitionem
4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride

4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
CAS#122111-03-9

CAS#122111-03-9

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
CAS NO.122111-03-9

CAS NO.122111-03-9

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS NO.122111-03-9

Lege plusMitte Inquisitionem
CAS 122111-03-9

CAS 122111-03-9

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS 122111-03-9

Lege plusMitte Inquisitionem
122111-03-9

122111-03-9

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
Quiescere potes ex officina nostra emere Gemcitabine HCl in Sinis. Pharmaceutical Run'an professionalis Sinarum Gemcitabine HCl fabrica et supplementum, qualitas products alta praebere possumus. Grata res emendas ex officina nostra.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept